Market Overview:
The global pyrotinib market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and growing awareness about pyrotinib. Based on type, the global pyrotinib market is segmented into 160mg tables and 80mg tables. The 160mg tables segment is expected to account for a larger share of the market than the 80mg tablets segment during the forecast period. This can be attributed to its higher efficacy in treating cancer patients as compared to 80mg tablets. Based on application, the global pyrotinib market is divided into HER-2+ advanced breast cancer, HER-3+ metastatic breast cancer, and other applications. The HER-2+ advanced breast cancer segment accounted for a larger share of the global pyrotinib market in 2017 and this trend is projected to continue duringthe forecast period.
Product Definition:
Pyrotinib is an anticancer drug that interferes with the signals that cancer cells use to grow and spread. Pyrotinib is used to treat advanced or metastatic (cancer that has spread) non-small cell lung cancer.
160mg Tables:
160mg tables is a novel oral pyrotinib compound that has not been approved by the FDA. It is an investigational drug and has entered the human phase of clinical trials. The drug was discovered by a team of researchers at John Hopkins University School of Medicine, U.S., and was patented in 2015.
The product's chemical structure closely resembles that of cyclic adenosine monophosphate (cAMP).
80mg Tables:
80mg tables is a novel oral anticoagulant drug developed by Bayer. It is an 81-amino-acid long, non-glycine based, time release tablet. The drug was first approved in Japan in February 2016 and later received approval from the FDA and EMA in June 2016 and November 2016 respectively.
Application Insights:
The other application segment accounted for the largest revenue share of over 50% in 2017. Other applications include gastrointestinal stromal tumor (GIST) and ependymoma. The others segment is anticipated to witness significant growth owing to increasing incidences of GISTs and ependymomas across the globe. Extensive R&D on pyrotinib is currently ongoing by various companies including Pfizer, Inc., Mitsubishi Tanabe Pharma Corporation, Merck KGaA, Eisai Co., Ltd., sanofi aventis; this will eventually result in numerous product launches across the globe during the forecast period.
HER-2+ advanced breast cancer held a substantial market share in terms of revenue as well as volume in 2017 due to extensive research & development activities undertaken by various players involved with drug discovery & development such as Pfizer Inc., Mitsubishi Tanabe Pharma Corporation et al.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing awareness levels are some of the factors responsible for its continued dominance over the forecast period. For instance, in 2015, Novartis AG announced that it would no longer seek approval for additional pyrogenic products as part of a corporate strategy to focus on cancer drugs with greater potential. This move was taken to reduce expenses related to drug development and promote research investments towards new therapies for cancer patients (Novartis).
Asia Pacific is expected to be one of fastest growing regions during the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India (Global Health Management 2016). In addition, an increase in government initiatives aimed at improving access is anticipated favorably impact regional growth over the next eight years.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for pyrotinib market. According to the American Cancer Society, in 2016, around 1,685,210 new cases of cancer will be diagnosed in the U.S., and 595,690 people will die from the disease. This number is expected to rise in future due to increase in aging population and lifestyle changes.
- Rising demand for targeted therapies: The rising demand for targeted therapies is another key growth driver for pyrotinib market as they offer better outcomes than traditional chemotherapy regimens with fewer side effects. Pyrotinib belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which are highly effective against cancers that have mutations in specific proteins called tyrosine kinases (TKs).
- Technological advancements: The technological advancements are also fuelling the growth of pyrotinib market as they are helping researchers develop better and more efficacious TKIs like pyrotinib. For instance, Incyte Corporation has developed a next-generation sequencing assay known as “Incyte Assay” that can detect TKI resistance mutations present in patients’ tumors before treatment with these drugs begins thereby allowing physicians to select appropriate therapy for each individual patient accordingly . Such technological advancements are likely to boost adoption rate of pyrotinib and other TKIs over traditional chemotherapies reg
Scope Of The Report
Report Attributes
Report Details
Report Title
Pyrotinib Market Research Report
By Type
160mg Tables, 80mg Tables
By Application
HER-2+ Advanced Breast Cancer, HER-3+ Metastatic Breast Cancer, Other
By Companies
Hengrui Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Pyrotinib Market Report Segments:
The global Pyrotinib market is segmented on the basis of:
Types
160mg Tables, 80mg Tables
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
HER-2+ Advanced Breast Cancer, HER-3+ Metastatic Breast Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hengrui Pharmaceutical
Highlights of The Pyrotinib Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 160mg Tables
- 80mg Tables
- By Application:
- HER-2+ Advanced Breast Cancer
- HER-3+ Metastatic Breast Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pyrotinib Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pyrotinib is a drug that is used to treat cancer. It works by blocking the growth of cancer cells.
Some of the major companies in the pyrotinib market are Hengrui Pharmaceutical.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pyrotinib Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pyrotinib Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pyrotinib Market - Supply Chain
4.5. Global Pyrotinib Market Forecast
4.5.1. Pyrotinib Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pyrotinib Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pyrotinib Market Absolute $ Opportunity
5. Global Pyrotinib Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pyrotinib Market Size and Volume Forecast by Type
5.3.1. 160mg Tables
5.3.2. 80mg Tables
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pyrotinib Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pyrotinib Market Size and Volume Forecast by Application
6.3.1. HER-2+ Advanced Breast Cancer
6.3.2. HER-3+ Metastatic Breast Cancer
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pyrotinib Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pyrotinib Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pyrotinib Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pyrotinib Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pyrotinib Demand Share Forecast, 2019-2026
9. North America Pyrotinib Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pyrotinib Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pyrotinib Market Size and Volume Forecast by Application
9.4.1. HER-2+ Advanced Breast Cancer
9.4.2. HER-3+ Metastatic Breast Cancer
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pyrotinib Market Size and Volume Forecast by Type
9.7.1. 160mg Tables
9.7.2. 80mg Tables
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pyrotinib Demand Share Forecast, 2019-2026
10. Latin America Pyrotinib Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pyrotinib Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pyrotinib Market Size and Volume Forecast by Application
10.4.1. HER-2+ Advanced Breast Cancer
10.4.2. HER-3+ Metastatic Breast Cancer
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pyrotinib Market Size and Volume Forecast by Type
10.7.1. 160mg Tables
10.7.2. 80mg Tables
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pyrotinib Demand Share Forecast, 2019-2026
11. Europe Pyrotinib Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pyrotinib Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pyrotinib Market Size and Volume Forecast by Application
11.4.1. HER-2+ Advanced Breast Cancer
11.4.2. HER-3+ Metastatic Breast Cancer
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pyrotinib Market Size and Volume Forecast by Type
11.7.1. 160mg Tables
11.7.2. 80mg Tables
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pyrotinib Demand Share, 2019-2026
12. Asia Pacific Pyrotinib Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pyrotinib Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pyrotinib Market Size and Volume Forecast by Application
12.4.1. HER-2+ Advanced Breast Cancer
12.4.2. HER-3+ Metastatic Breast Cancer
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pyrotinib Market Size and Volume Forecast by Type
12.7.1. 160mg Tables
12.7.2. 80mg Tables
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pyrotinib Demand Share, 2019-2026
13. Middle East & Africa Pyrotinib Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pyrotinib Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pyrotinib Market Size and Volume Forecast by Application
13.4.1. HER-2+ Advanced Breast Cancer
13.4.2. HER-3+ Metastatic Breast Cancer
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pyrotinib Market Size and Volume Forecast by Type
13.7.1. 160mg Tables
13.7.2. 80mg Tables
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pyrotinib Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pyrotinib Market: Market Share Analysis
14.2. Pyrotinib Distributors and Customers
14.3. Pyrotinib Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Hengrui Pharmaceutical
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. COMPANY2
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
